Explosive Hot Cannabis Marijuana POT stock is PLPL for 2017 & 2018. This stock seems to explode at any time because it is down below the multi support levels and I see they are in the business of exciting cannabis space. Looking at the history of this stock performance, it has came up pretty handsomely. After research I found that Plandaí Biotechnology is the culmination of over ten years of research in the field of plant extracts. Its principle holdings consist of land, farms and infrastructure, totaling more than 7500 acres, in the province of Mpumalanga, South Africa.
After research I found that Plandai Biotechnology Sets Aggressive Agenda for 2017. According to the COO, Plandaí's work in the clinic will include:
Finalizing the production protocols for both tomato and citrus Phytofare® extracts
Clinical investigations that seek to establish that Phytofare® catechins delivered in chicken feed will inhibit and protect poultry against salmonella and gastrointestinal infections, improve food conversion rates, and reduce mortality
Additionally, Plandaí has granted a research license to Protext Mobility to develop pharmaceutical applications involving Phytofare®. Protext will be conducting a human study using Phytofare® to regulate glucose levels in Type 2 diabetics as well as, taking over the research to establish a platform for producing non-psychoactive Cannabis. Plandaí states that the plan for Protext is to produce a Phytofare® complex containing bioavailable cannabinoids, cannabinoid acids, and polyphenols that will be formulated into an oral delivery system. Reference link is
http://www.marketwired.com/press-release/plan...210548.htm
Protext Pharma, Inc., formerly Protext Mobility, Inc., is a biotechnology firm engaged in the development of pharmaceutical applications for the bioavailable Phytofare catechin complex. The company has market cap of $2.16 million. The Firm operates through two subsidiaries: Plandai Biotechnology South Africa and Cannabis Biosciences Inc. he Company’s business units include Cannabis Biosciences, which focuses on developing cannabis extracts under legal government licenses and permits, and Plandai Biotechnology South Africa, which is engaged in the research and clinical testing of bioceutical products, all natural ingredients formulated for pharmaceutical applications and processed under pharma-grade conditions.
Products and benefits
"BIOAVAILABILITY" can be defined as a measurement of the amount of compound absorbed into the bloodstream.
In the market today, green tea high purity EGCG extracts, with an average selling price of $500/kg, have poor bioavailability of between 1-10%. Plandaí proprietary plant extracts has shown, in published studies, to have increased bioavailability. We believe through our studies that this is between 60-80%, far exceeding anything currently available today.
Our extracts include but are not limited to, gallate catechins from green tea, (catechin gallate (CG),epigallocatechin gallate (EGCG), gallocatechin gallate (GCG), and epicatechin gallate (ECG); carotenoids (lycopene)from tomatoes, as well as citrus bioflavonoids and limonoids. Furthermore, Plandaí's gallate catechin extract will be the active ingredient in formulated products supporting weight loss, antiaging, the lowering of blood cholesterol, the regulation of high blood pressure and controlling diabetes 1 and 2.
This means, that Plandaí's extracts deliver a more meaningful and beneficial dose at highly competitive prices to the consumer, in wellness terms
The Northern American and European natural extracts market are emerging and in a state of intense competition. The shift towards natural ingredients is driving the expansion of the natural extracts market. Among the flurry of ingredients competing in the natural extracts market, green tea extracts is a pioneer and one of the most prominent success stories. (Frost & Sullivan Research, 2011).
Detail information can be found regarding Research and Development from the following company site link:
http://www.plandaibiotech.com/clinical-trials.html
Also you can find more information regarding current projects from the following company website link:
http://www.plandaibiotech.com/current-projects.html
I found out that PLPL entered into Medical Marijuana Field With Phyto Cannabinoid Extract. The link provide more information:
http://www.marketwired.com/press-release/plan...846415.htm
ProText Mobility, the company had announced that it would be making a strategic acquisition through an all-stock deal with Plandai Biotechnology Inc (OTCMKTS
LPL) for its Cannabis Biosciences subsidiary. ProText Pharma Inc (OTCMKTS:TXTM)’s Cannabis Extract May Get Green Light in South Africa. I found this link for more info:
http://streetregister.com/2017/10/11/protext-...th-africa/
After research I found that Plandai Biotechnology Sets Aggressive Agenda for 2017. According to the COO, Plandaí's work in the clinic will include:
Finalizing the production protocols for both tomato and citrus Phytofare® extracts
Clinical investigations that seek to establish that Phytofare® catechins delivered in chicken feed will inhibit and protect poultry against salmonella and gastrointestinal infections, improve food conversion rates, and reduce mortality
Additionally, Plandaí has granted a research license to Protext Mobility to develop pharmaceutical applications involving Phytofare®. Protext will be conducting a human study using Phytofare® to regulate glucose levels in Type 2 diabetics as well as, taking over the research to establish a platform for producing non-psychoactive Cannabis. Plandaí states that the plan for Protext is to produce a Phytofare® complex containing bioavailable cannabinoids, cannabinoid acids, and polyphenols that will be formulated into an oral delivery system. Reference link is
http://www.marketwired.com/press-release/plan...210548.htm
Protext Pharma, Inc., formerly Protext Mobility, Inc., is a biotechnology firm engaged in the development of pharmaceutical applications for the bioavailable Phytofare catechin complex. The company has market cap of $2.16 million. The Firm operates through two subsidiaries: Plandai Biotechnology South Africa and Cannabis Biosciences Inc. he Company’s business units include Cannabis Biosciences, which focuses on developing cannabis extracts under legal government licenses and permits, and Plandai Biotechnology South Africa, which is engaged in the research and clinical testing of bioceutical products, all natural ingredients formulated for pharmaceutical applications and processed under pharma-grade conditions.
Products and benefits
"BIOAVAILABILITY" can be defined as a measurement of the amount of compound absorbed into the bloodstream.
In the market today, green tea high purity EGCG extracts, with an average selling price of $500/kg, have poor bioavailability of between 1-10%. Plandaí proprietary plant extracts has shown, in published studies, to have increased bioavailability. We believe through our studies that this is between 60-80%, far exceeding anything currently available today.
Our extracts include but are not limited to, gallate catechins from green tea, (catechin gallate (CG),epigallocatechin gallate (EGCG), gallocatechin gallate (GCG), and epicatechin gallate (ECG); carotenoids (lycopene)from tomatoes, as well as citrus bioflavonoids and limonoids. Furthermore, Plandaí's gallate catechin extract will be the active ingredient in formulated products supporting weight loss, antiaging, the lowering of blood cholesterol, the regulation of high blood pressure and controlling diabetes 1 and 2.
This means, that Plandaí's extracts deliver a more meaningful and beneficial dose at highly competitive prices to the consumer, in wellness terms
The Northern American and European natural extracts market are emerging and in a state of intense competition. The shift towards natural ingredients is driving the expansion of the natural extracts market. Among the flurry of ingredients competing in the natural extracts market, green tea extracts is a pioneer and one of the most prominent success stories. (Frost & Sullivan Research, 2011).
Detail information can be found regarding Research and Development from the following company site link:
http://www.plandaibiotech.com/clinical-trials.html
Also you can find more information regarding current projects from the following company website link:
http://www.plandaibiotech.com/current-projects.html
I found out that PLPL entered into Medical Marijuana Field With Phyto Cannabinoid Extract. The link provide more information:
http://www.marketwired.com/press-release/plan...846415.htm
ProText Mobility, the company had announced that it would be making a strategic acquisition through an all-stock deal with Plandai Biotechnology Inc (OTCMKTS
LPL) for its Cannabis Biosciences subsidiary. ProText Pharma Inc (OTCMKTS:TXTM)’s Cannabis Extract May Get Green Light in South Africa. I found this link for more info: http://streetregister.com/2017/10/11/protext-...th-africa/
Marijuana Stocks Millionaire Club
Quote:Timing is everything.
